https://www.schlieren.ch/standortfoerderung  

8952 Schlieren, Freiestrasse 6

  +41 44 738 14 11
 stadtbuero@schlieren.ch

Location Promotion strengthens the dialog between politics, administration and business and maintains a large network of contacts. It implements the city's economic strategy, promotes young entrepreneurship, provides advice on company relocations and arranges office and commercial space. It also strengthens Schlieren as a business location by devising individual development strategies for underutilized sites.

https://ghzschlieren.ch/  

8952 Schlieren, Wagistrasse 23

 +41 44 730 83 21
 info@ghzschlieren.ch

The Wagiareal in Schlieren has undergone major construction in recent years. Successful companies in the biotech, communications and administration sectors have established themselves in recent years. The excellently developed real estate optimally supports the companies in achieving their goals. In the future, new office and commercial space for trade, commerce and manufacturing will be created on an ongoing basis. The new projects are being developed in connection with and with synergies of the existing properties. They allow for individual rental space in various sizes, locations and fit-out standards. Not only will you receive suitable space according to your requirements, but we will also take into account your expansion wishes and expansion options. possibilities. Expansion financing, fair rental prices, uncomplicated contract processing and an open ear for our tenants are a matter of course for us.

https://www.roche.ch/en/sites/schlieren  

8952 Schlieren, Wagistrasse 10

 +41 43 215 10 00

The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.

https://www.wysszurich.ch/projects/somagenetix  

8952 Schlieren, Wagistrasse 23

Gene therapy solutions for patients with severe inherited diseases.